The device is intended to fix an ACL graft with a single fluid motion to maintain graft tension and reduce surgery time and instrumentation.
The company anticipates applying for clearance from the U.S. Food and Drug Administration and approvals in key markets across the world, and estimates product launch within two years.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws
